Flumatinib mesylate - CAS 895519-91-2
Catalog number: 895519-91-2
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C30H33F3N8O4S
Molecular Weight:
658.69
COA:
Inquire
Targets:
Bcr-Abl
Description:
Flumatinib mesylate, a derivative of imatinib, is a multi-kinase inhibitor for c-Abl, PDGFRβ and c-Kit. It is currently in Phase I and II clinical trials in China for the treatment of chronic myelogenous leukemia (CML). It effectively overcomes drug resistance of certain KIT mutants. It can reduce the expression of C-MYC, HIF-1 α and VEGF in U266 cell line in a time- and dose-dependent manners.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
HH-GV-678 mesylate
MSDS:
Inquire
1.[Effect of flumatinib mesylate on C-MYC, HIF-1α and VEGF in U226 line].
Chang MX1, Ma YP2. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Dec;21(6):1496-500. doi: 10.7534/j.issn.1009-2137.2013.06.024.
The objective of this study was to investigate the effect of the new generation of tyrosine kinase inhibitor flumatinib mesylate on C-MYC, HIF-1α and VEGF in multiple myeloma (MM) cell line U266. Different concentrations (1, 5, 10 µmol/L) of flumatinib mesylate were used to act on U266 cell line for 8, 16 and 24 h, and the expression of C-MYC, and HIF-1α genes was detected by real-time fluorescence-quantitative PCR, the expression of C-MYC, HIF-1α and VEGF was measured by Western blot. The results showed that the gene expression of C-MYC and HIF-1 genes decreased gradually with the increasing of flumatinib mesylate concentration (P < 0.05). At the same concentration of flumatinib mesylate, the expression of C-MYC and HIF-1α gene decreased gradually with prolonging of treatment time with the flumatinib mesylate (P < 0.05). When the flumatinib mesylate acted the U266 cell line for 16 h, the expression of C-MYC, HIF-1α and VEGF decreased gradually with the increasing of flumatinib mesylate concentration (P < 0.
2.Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.
Zhao J1, Quan H, Xu Y, Kong X, Jin L, Lou L. Cancer Sci. 2014 Jan;105(1):117-25. doi: 10.1111/cas.12320. Epub 2014 Jan 4.
Activating mutations in KIT have been associated with gastrointestinal stromal tumors (GISTs). The tyrosine kinase inhibitor imatinib mesylate has revolutionized the treatment of GISTs. Unfortunately, primary or acquired resistance to imatinib does occur in GISTs and forms a major problem. Although sunitinib malate, a multi-kinase inhibitor, has shown effectiveness against imatinib-resistant GISTs, recent studies have indicated that some imatinib-resistant GISTs harboring secondary mutations in the KIT activation loop were also resistant to sunitinib. Therefore, new drugs capable of overcoming the dual drug resistance of GISTs probably have potential clinical utility. In this study, we investigated the efficacy of flumatinib, an inhibitor of BCR-ABL/PDGFR/KIT, against 32D cells transformed by various KIT mutants and evaluated its potency to overcome the drug resistance of certain mutants. Interestingly, our in vitro study revealed that flumatinib effectively overcame the drug resistance of certain KIT mutants with activation loop mutations (i.
3.Simultaneous determination of flumatinib and its two major metabolites in plasma of chronic myelogenous leukemia patients by liquid chromatography-tandem mass spectrometry.
Yang Y1, Liu K, Zhong D, Chen X. J Chromatogr B Analyt Technol Biomed Life Sci. 2012 May 1;895-896:25-30. doi: 10.1016/j.jchromb.2012.03.008. Epub 2012 Mar 15.
Flumatinib is an antineoplastic tyrosine kinase inhibitor used for the treatment of chronic myelogenous leukemia (CML). Its major metabolites in the circulation are N-desmethyl flumatinib (M1) and amide hydrolysis product (M3). To investigate the pharmacokinetics of flumatinib in CML patients, a simple, specific and rapid liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated for the simultaneous determination of flumatinib and its two major metabolites in patient plasma. After a simple, one-step protein precipitation with methanol, flumatinib, its two metabolites, and internal standard (HHGV-E) were separated on a C(18) column using an isocratic mobile phase of methanol:5mM ammonium acetate:formic acid (60:40:0.4, v/v/v). A total chromatographic run time of 4.2 min was achieved. The detection was performed in multiple reaction monitoring mode, using the transitions of m/z 563→m/z 463 for flumatinib, m/z 549→m/z 463 for M1, m/z 303→m/z 175 for M3, and m/z 529→m/z 429 for HHGV-E.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Bcr-Abl Products


CAS 641571-10-0 Nilotinib

Nilotinib
(CAS: 641571-10-0)

Nilotinib is a Bcr-Abl inhibitor with IC50 less than 30 nM.

CAS 926037-48-1 Radotinib

Radotinib
(CAS: 926037-48-1)

Radotinib, also known as IY-5511, is an orally available, hydrochloride salt form of radotinib, a second-generation tyrosine kinase inhibitor of Bcr-Abl fusion ...

CAS 943319-70-8 Ponatinib

Ponatinib
(CAS: 943319-70-8)

Ponatinib is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM, respectively.

CAS 690206-97-4 ZM306416

ZM306416
(CAS: 690206-97-4)

ZM306416 is a vascular endothelial growth factor receptor (VEGFR) antagonist.

CAS 1492952-76-7 Asciminib

Asciminib
(CAS: 1492952-76-7)

Asciminib, also known as ABL001, is a potent and selective allosteric Bcr-Abl inhibitor. Asciminib inhibits Ba/F3 cells grown with an IC50 of 0.25 nM.

CAS 302962-49-8 Dasatinib

Dasatinib
(CAS: 302962-49-8)

Dasatinib, also known as BMS-354825, is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and...

CAS 260415-63-2 PD-173955

PD-173955
(CAS: 260415-63-2)

PD-173955 is a src tyrosine kinase inhibitor. PD173955 inhibited Bcr-Abl-dependent cell growth. PD173955 showed cell cycle arrest in G(1). PD173955 has an IC(50...

CHMFL-ABL-053
(CAS: 1808287-83-3)

CHMFL-ABL-053 is a potent and orally available inhibitor of BCR-ABL (IC50 = 70nM) without inhibitory activity against c-KIT kinase that is a common target of BC...

CAS 887650-05-7 Bafetinib

Bafetinib
(CAS: 887650-05-7)

Bafetinib is a potent and selective dual Bcr-Abl/Lyn inhibitor, but it does not inhibit the phosphorylation of the T315I mutant and is less potent to PDGFR and ...

CAS 778277-15-9 GNF-5

GNF-5
(CAS: 778277-15-9)

CAS 839706-07-9 GNF-7

GNF-7
(CAS: 839706-07-9)

GNF-7 is a type-II T315I inhibitor. GNF-7 inhibits Ack1 and germinal center kinase (GCK). GNF-7 is among the first type-II inhibitors capable of inhibiting T315...

CAS 895519-91-2 Flumatinib mesylate

Flumatinib mesylate
(CAS: 895519-91-2)

Flumatinib mesylate, a derivative of imatinib, is a multi-kinase inhibitor for c-Abl, PDGFRβ and c-Kit. It is currently in Phase I and II clinical trials in Chi...

CAS 778270-11-4 GNF-2

GNF-2
(CAS: 778270-11-4)

CAS 1020172-07-9 Rebastinib

Rebastinib
(CAS: 1020172-07-9)

Rebastinib is an orally bioactive inhibitor of Bcr-Abl that binds to and inhibits Bcr-Abl fusion oncoprotein. Rebastinib changes the conformation of the folded ...

CAS 859212-16-1 Bafetinib

Bafetinib
(CAS: 859212-16-1)

Bafetinib, also known as INNO-406, is an orally bioavailable 2-phenylaminopyrimidine derivative with potential antineoplastic activity. Bafetinib specifically ...

CAS 484049-04-9 DPH

DPH
(CAS: 484049-04-9)

DPH is a potent cell permeable c-Abl activator. It binds and alters the conformation of the myristoyl binding site of c-Abl tyrosine kinase. DPH exhibits potent...

CAS 1257628-77-5 GZD824

GZD824
(CAS: 1257628-77-5)

GZD824 potently suppressed proliferation of Bcr-Abl-positive K562 and Ku812 human CML cells with IC(50) values of 0.2 and 0.13 nM, respectively. It also display...

CAS 923288-90-8 Nilotinib monohydrochloride monohydrate

Nilotinib monohydrochloride monohydrate
(CAS: 923288-90-8)

Nilotinib monohydrochloride monohydrate is an orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. It ...

CAS 854001-07-3 Dasatinib hydrochloride

Dasatinib hydrochloride
(CAS: 854001-07-3)

Dasatinib hydrochloride is a potent and dual Abl/ Src inhibitor. It inhibits c-Kit (WT)/c-Kit (D816V).

Chemical Structure

CAS 895519-91-2 Flumatinib mesylate

Quick Inquiry

Verification code

Featured Items